Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy. According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, to Novo Nordisk for $11 billion. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, which makes the blockbuster GLP-1 injectable weight-loss drug Wegovy.